213 related articles for article (PubMed ID: 34990894)
1. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
[TBL] [Abstract][Full Text] [Related]
2. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
[TBL] [Abstract][Full Text] [Related]
4. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
[TBL] [Abstract][Full Text] [Related]
5. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
[TBL] [Abstract][Full Text] [Related]
6. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
[TBL] [Abstract][Full Text] [Related]
7. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
8. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
9. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
10. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic Processing of Neurexins by Presenilins Sustains Synaptic Vesicle Release.
Servián-Morilla E; Robles-Lanuza E; Sánchez-Hidalgo AC; Camacho-Garcia RJ; Paez-Gomez JA; Mavillard F; Saura CA; Martinez-Mir A; Scholl FG
J Neurosci; 2018 Jan; 38(4):901-917. PubMed ID: 29229705
[TBL] [Abstract][Full Text] [Related]
12. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
[TBL] [Abstract][Full Text] [Related]
14. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
15. Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers.
Camporesi E; Lashley T; Gobom J; Lantero-Rodriguez J; Hansson O; Zetterberg H; Blennow K; Becker B
Acta Neuropathol Commun; 2021 Feb; 9(1):19. PubMed ID: 33522967
[TBL] [Abstract][Full Text] [Related]
16. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
17. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders.
Nilsson J; Cousins KAQ; Gobom J; Portelius E; Chen-Plotkin A; Shaw LM; Grossman M; Irwin DJ; Trojanowski JQ; Zetterberg H; Blennow K; Brinkmalm A
Alzheimers Dement; 2023 May; 19(5):1775-1784. PubMed ID: 36239248
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
